Drug intelligence / Profile preview

BR011

Development stage: Preclinical
Lead developer: Brise Pharmaceuticals

Overview

BR011 is an early-stage therapeutic candidate being developed by Brise Pharmaceuticals for the treatment of neuropathic pain. Currently in the discovery phase, the drug's specific molecular target and therapeutic modality have not been publicly disclosed by the developer. BR011 is part of Brise Pharmaceuticals' broader pipeline focused on central nervous system (CNS) disorders and pain management, which includes other assets such as the CGRP antagonist BR005 for migraine.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on BR011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR011.

Explore the full profile